XML 72 R22.htm IDEA: XBRL DOCUMENT
v3.25.2

COMMON SHARES | 12 Months Ended
--- | ---
Jun. 30, 2025
Equity [Abstract] |
COMMON SHARES |
| 10. | COMMON SHARES
| a) | Issuances
Fiscal Year 2025 Issuances On November 5, 2024, the Company closed an underwritten public offering (the “November 2024 Registered Offering”), pursuant to the underwriting agreement, dated November 3, 2024 (the “Underwriting Agreement”), with Maxim Group LLC (“Maxim”), as underwriter, which consisted of 1,592,356 Common Shares, 1,672,090 Warrants (the “Series A Public Warrants”) to purchase up to an additional 1,672,090 Common Shares and 836,045 Warrants (the “Series B Public Warrants” and, together with the Series A Public Warrants, the “November 2024 Public Warrants”) to purchase up to an additional 836,045 Common Shares. Each Common Share was sold together with one Series A Public Warrant and one-half of one Series B Public Warrant at a combined public offering price of $1.57. The gross proceeds from the November 2024 Registered Offering were $2,501 before deducting underwriting discounts and offering expenses. The November 2024 Public Warrants were classified as equity instruments and accordingly, the net proceeds were allocated based on the relative fair values of the Common Shares and the November 2024 Public Warrants on the date of issuance, with $943 allocated to the fair value of the November 2024 Public Warrants and the balance of the proceeds of $1,558 allocated to Common Shares. The Company incurred total transaction costs related to the November 2024 Registered Offering $1,226, which were treated as share issuance costs at closing. The Series A Public Warrants have an exercise price of $1.75 per underlying Common Share, are exercisable immediately, and will expire on November 5, 2026. The Series B Public Warrants have an exercise price of $2.07 per underlying Common Share, are exercisable beginning six months and one day from the date of issuance and will expire on November 5, 2029. In addition, pursuant to the Underwriting Agreement, the Company granted Maxim a 45-day over-allotment option to purchase (i) 238,853 additional Common Shares and (ii) 358,280 Option Warrants (as defined below) to purchase up to an aggregate of 358,280 Common Shares. “Option Warrant” means one Series A Public Warrant combined with one-half of one Series B Public Warrant. On November 4, 2024, Maxim partially exercised its over-allotment option to purchase 79,734 additional Series A Public Warrants and 39,867 additional Series B Public Warrants, which amounts are included in the amounts discussed above and were issued at closing of the November 2024 Registered Offering. The following table discloses the primary inputs for the Black-Scholes model used in valuing the November 2024 Public Warrants:
Schedule of Black-Scholes model used in public warrants |  | November 5, 2024 |
November 2024 Public Warrants: |  | Series A Public Warrants |  |  | Series B Public Warrants |
Closing Common Share price |  | $ | 1.455 |  |  | $ | 1.455 |
Term (years) |  |  | 4.5 |  |  |  | 2.0 |
Historic equity volatility |  |  | 67.43 | % |  |  | 67.13 | %
Risk-free rate |  |  | 4.14 | % |  |  | 4.20 | %
On November 13, 2024, the Company closed a non-brokered private placement (the “November 2024 Private Offering”), pursuant to binding subscription agreements with certain accredited investors as part of a non-brokered private placement of 2,199,602 units of the Company (the “November 2024 Units”). Each November 2024 Unit consisted of one Common Share, one Warrant (a “Series A Private Warrant”) to purchase one Common Share, and one-half of one Warrant (each whole such Warrant, a “Series B Private Warrant” and, together with the Series A Private Warrants, the “November 2024 Private Warrants”), with each Series B Private Warrant entitling the holder thereof to purchase one additional Common Share. Each November 2024 Unit was issued and sold at a price of $1.57. The gross proceeds of the November 2024 Private Offering were approximately $3,500 before deducting offering expenses. Certain directors and officers of the Company (the “Insider Investors”) purchased November 2024 Units at a price of $1.7675 per November 2024 Unit, which price includes $0.1975 per November 2024 Private Warrant and allowed such directors and officers to participate in the November 2024 Private Offering in accordance with the rules of the Nasdaq. The Series A Private Warrants have an exercise price of $1.75 per underlying Common Share, are exercisable immediately, and will expire on November 13, 2026. The Series B Private Warrants have an exercise price of $2.07 per underlying Common Share, are exercisable beginning six months and one day from the date of issuance and will expire on November 13, 2029. The Company recorded a non-cash expense of $34 and $110 to other operating expenses and employee related costs, respectively, representing the excess of fair value of the November 2024 Units over the purchase price paid by Insider Investors. Based upon the Company’s analysis of the criteria contained in ASC 815, the Company determined that the November 2024 Private Warrants met the definition of a derivative liability, as any Warrant exercise that could cause the holder to exceed 19.9% ownership of NioCorp Common Shares would require shareholder approval. As such, the November 2024 Private Warrants were recognized as warrant liabilities on the consolidated balance sheet and were measured at their issuance date fair value of $1,928 and subsequently remeasured at each reporting period with changes being recorded as a non-operating gain or loss in the consolidated statement of operations and comprehensive loss. The remaining proceeds of the November 2024 Private Offering of $1,573 were allocated to Common Shares. The Company incurred total transaction costs related to the November 2024 Private Offering of $161, of which $60 was allocated to the November 2024 Private Warrants and was expensed at closing. The following tables disclose the primary inputs for the Black-Scholes model used in valuing the November 2024 Private Warrants:
Schedule of Black-Scholes model used in Private warrants |  | November 13, 2024 |
November 2024 Private Warrants: |  | Series A Private Warrants |  |  | Series B Private Warrants |
Closing Common Share price |  | $ | 1.49 |  |  | $ | 1.49 |
Term (years) |  |  | 2.0 |  |  |  | 4.5 |
Historic equity volatility |  |  | 67.26 | % |  |  | 67.52 | %
Risk-free rate |  |  | 4.20 | % |  |  | 4.30 | %
|  | June 30, 2025 |
November 2024 Private Warrants: |  | Series A Private Warrants |  |  | Series B Private Warrants |
Closing Common Share price |  | $ | 2.33 |  |  | $ | 2.33 |
Term (years) |  |  | 1.37 |  |  |  | 4.38 |
Historic equity volatility |  |  | 86.14 | % |  |  | 74.26 | %
Risk-free rate |  |  | 3.88 | % |  |  | 3.77 | %
The following table sets forth a summary of the changes in the fair value of the November 2024 Private Warrants liabilities:
Schedule of changes in the fair value of Private Warrants liabilities |  | November 2024 Private Warrants |
Fair value at issuance (November 13, 2024) |  | $ | 1,929 |
Fair value of Warrants exercised |  |  | (338 | )
Change in fair value |  |  | 2,240 |
Fair value as of June 30, 2025 |  | $ | 3,831 |
On January 31, 2025, the Company closed an underwritten registered direct offering (the “January 2025 Offering”), pursuant to an underwriting agreement, dated January 29, 2025, with Maxim, as underwriter, pursuant to which the Company issued and sold 2,577,320 Common Shares, 2,577,320 Series A Warrants to purchase up to 2,577,320 Common Shares (the “January 2025 Series A Warrants”) and 1,288,660 Series B Warrants to purchase up to an additional 1,288,660 Common Shares (the “January 2025 Series B Warrants” and, together with the January 2025 Series A Warrants, the “January 2025 Warrants”). Each Common Share was sold together with one January 2025 Series A Warrant and one-half of one January 2025 Series B Warrant at a combined public offering price of $1.94. The gross proceeds from the January 2025 Offering were approximately $5,000 before deducting underwriting discounts and offering expenses. The January 2025 Warrants were classified as equity instruments, and accordingly, the net proceeds were allocated based on the relative fair values of the Common Shares and the January 2025 Warrants on the date of issuance, with $2,200 allocated to the fair value of the January 2025 Warrants and the balance of the proceeds of $2,800 allocated to Common Shares. The Company incurred total transaction costs related to the January 2025 Offering of $799, which were treated as share issuance costs at closing. The January 2025 Series A Warrants have an exercise price of $1.98 per underlying Common Share, are exercisable immediately, and will expire on August 2, 2027. The January 2025 Series B Warrants have an exercise price of $2.05 per underlying Common Share, are exercisable immediately, and will expire on January 31, 2029. The following primary inputs were used in the Black-Scholes model for valuing the January 2025 Warrants:
Schedule of Black-Scholes model for warrants |  | Series A Public Warrants |  |  | Series B Public Warrants |
Closing Common Share price |  | $ | 2.25 |  |  | $ | 2.25 |
Term (years) |  |  | 2.5 |  |  |  | 4.0 |
Historic equity volatility |  |  | 73.18 | % |  |  | 73.36 | %
Risk-free rate |  |  | 4.23 | % |  |  | 4.31 | %
On April 21, 2025, the Company closed an underwritten public offering (the “April 2025 Offering”), pursuant to an underwriting agreement, dated April 17, 2025, with Maxim, as underwriter, pursuant to which the Company issued and sold (i) 6,628,846 Common Shares at a public offering price of $2.60 per Common Share and (ii) 1,063,462 pre-funded Warrants (the “April 2025 Pre-Funded Warrants”) to purchase up to an additional 1,063,462 Common Shares at a public offering price of $2.5999. The April 2025 Pre-Funded Warrants have an exercise price of $0.0001 per underlying Common Share, are exercisable immediately, and do not have an expiration date. On April 17, 2025, Maxim partially exercised its over-allotment option to purchase 323,504 additional Common Shares at closing. The gross proceeds from the April 2025 Offering were approximately $20,841 before deducting underwriting discounts and offering expenses. The April 2025 Pre-Funded Warrants were classified as equity instruments and accordingly, the net proceeds were allocated based on the relative fair values of the Common Shares and the April 2025 Pre-Funded Warrants on the date of issuance, with $2,765 allocated to the fair value of the April 2025 Pre-Funded Warrants (based on the value of the underlying Common Shares at closing) and the balance of the proceeds of $18,076 allocated to Common Shares. The Company incurred total transaction costs related to the April 2025 Offering of $2,102, which were treated as share issuance costs at closing. Fiscal Year 2024 Issuances On September 1, 2023, the Company closed a non-brokered private placement of units of the Company (the “September 2023 Units”). A total of 250,000 September 2023 Units were issued at a price per September 2023 Unit of $4.00, for total gross proceeds to the Company of $1,000. Each September 2023 Unit consists of one Common Share and one Warrant (“September 2023 Warrant”). Each September 2023 Warrant entitles the holder to acquire one Common Share at a price of $4.60 at any time prior to September 1, 2025. The September 2023 Warrants were classified as an equity instrument and accordingly, the net proceeds of $962 were allocated based on the relative fair values of the Common Shares and the September 2023 Warrants on the date of issuance. The amount allocated to the fair value of the September 2023 Warrants was $254 and the balance of the proceeds of $708 was allocated to the Common Shares. The fair value of the September 2023 Warrants issued was computed using the Black Scholes pricing model using the following assumptions: an expected life of 2.0 years, a risk-free interest rate of 4.85%, an expected volatility of 71.63%, and an expected dividend rate of 0%. On December 22, 2023, the Company closed a non-brokered private placement (the “December 2023 Private Placement”) of 413,432 units of the Company (the “December 2023 Units”). Each December 2023 Unit consists of one Common Share and one Warrant (“December 2023 Warrant”). Each December 2023 Warrant entitles the holder to acquire one Common Share at a price of $3.54 at any time until December 22, 2025. 274,587 of the December 2023 Units were issued and sold to certain accredited investors, who are not affiliated with the Company but with whom the Company had a pre-existing relationship, at a price of $3.08 per December 2023 Unit, and 138,845 of the December 2023 Units were issued and sold to certain officers and directors of the Company (the “Insider Investors”), at a price of $3.205 per December 2023 Unit. The price per December 2023 Unit paid by the Insider Investors included $0.125 per December 2023 Warrant underlying each December 2023 Unit purchased by the Insider Investors which allowed the Insider Investors to participate in the December 2023 Private Placement in accordance with the rules of Nasdaq. The Company received aggregate gross proceeds from the December 2023 Private Placement of approximately $1,290. The Company recorded a non-cash expense of $92 and $10 to other operating expense and employee related costs, respectively, representing the excess of fair value of the December 2023 Units over the purchase price paid by Insider Investors. The December 2023 Warrants were classified as an equity instrument and accordingly, the estimated net proceeds of $1,241 were allocated based on the relative fair values of the Common Shares and the December 2023 Warrants on the date of issuance. The amount allocated to the fair value of the December 2023 Warrants was $264 and the balance of the proceeds of $977 was allocated to the Common Shares. The fair value of the December 2023 Warrants issued was computed using the Black Scholes pricing model using the following assumptions: an expected life of 2.0 years, a risk-free interest rate of 4.33%, an expected volatility of 54.8%, and an expected dividend rate of 0%. On June 24, 2024, the Company closed a non-brokered private placement of units of the Company (the “June 2024 Units”). A total of 315,000 June 2024 Units were issued at a price per June 2024 Unit of $1.91, for total gross proceeds to the Company of $602. Each June 2024 Unit consists of one Common Share and one Warrant (“June 2024 Warrant”). Each June 2024 Warrant entitles the holder to acquire one Common Share at a price of $2.20 at any time prior to June 24, 2026. The June 2024 Warrants were classified as an equity instrument and accordingly, the net proceeds of $602 were allocated based on the relative fair values of the Common Shares and the June 2024 Warrants on the date of issuance. The amount allocated to the fair value of the June 2024 Warrants was $161 and the balance of the proceeds of $441 was allocated to Common Shares. The fair value of the June 2024 Warrants issued was computed using the Black Scholes pricing model using the following assumptions: an expected life of 2.0 years, a risk-free interest rate of 4.73%, an expected volatility of 73.92%, and an expected dividend rate of 0%. Yorkville Equity Facility Financing Agreement Issuances As of June 30, 2025, the Company has access to up to $46,917 in net proceeds from the Yorkville Equity Facility Financing Agreement. The Yorkville Equity Facility Financing Agreement expires on April 1, 2026. The Company issued the following Common Shares under the Yorkville Equity Facility Financing Agreement during the periods presented below:
Schedule of issued Common Shares under the Yorkville Equity Facility Financing Agreement |  | For The Year Ended June 30, |
|  | 2025 |  |  | 2024 |
Common Shares issued |  |  | 5,671,742 |  |  |  | 1,358,000 |
Gross funds received |  | $ | 12,352 |  |  | $ | 3,293 |
Market value of Common Shares issued |  |  | 12,941 |  |  |  | 3,398 |
Loss on issuance(1) |  | $ | 589 |  |  | $ | 105 |
| (1) | Loss on issuance represents a non-cash amount equal to the difference between the proceeds received and the fair value of the Common Shares issued based on the Nasdaq closing price per Common Share on the issuance date and is recorded in other operating expenses in the condensed consolidated statement of operations and comprehensive loss.
| b) | Stock Options
On January 19, 2024, the Company’s shareholders voted to approve an amendment and restatement of its long-term incentive plan (the “2017 Amended Long-Term Incentive Plan”) and the granting of incentive securities thereunder until January 19, 2027. Under the 2017 Amended Long-Term Incentive Plan, the Board may, in its discretion from time to time, grant Options and share units (in the form of restricted share units and performance share units), plus dividend equivalents, to non-employee directors, employees and certain other service providers (as described in the 2017 Amended Long-Term Incentive Plan) of the Company and affiliated entities selected by the Board. Subject to adjustment as described in the 2017 Amended Long-Term Incentive Plan, the aggregate number of Common Shares that may be reserved for issuance to participants under the 2017 Amended Long-Term Incentive Plan, together with all other security-based compensation arrangements of the Company, may not exceed 10% of the issued and outstanding Common Shares from time to time, and the Common Shares reserved for issuance upon settlement of share units will not exceed 5% of the issued and outstanding Common Shares from time to time. The 2017 Amended Long-Term Incentive Plan limits the maximum number of Common Shares issued to insiders (as defined under TSX rules for this purpose) within any 1-year period, or issuable to insiders at any time, in the aggregate, under all security-based compensation arrangements (including the 2017 Amended Long-Term Incentive Plan) to 10% of the then issued and outstanding Common Shares. The 2017 Amended Long-Term Incentive Plan also limits the aggregate number of Common Shares that may be reserved for issuance to any one participant under the 2017 Amended Long-Term Incentive Plan, together with all other security-based compensation arrangements of the Company, to 5% of the then issued and outstanding Common Shares (on a non-diluted basis). Subject to the adjustment provisions of the 2017 Amended Long-Term Incentive Plan, the aggregate number of Common Shares actually issued or transferred by the Company upon the exercise of Options will also be limited, as described in the 2017 Amended Long-Term Incentive Plan. The Board has power over the granting, amendment, administration, or settlement of any award. Option transactions are summarized as follows:
Schedule of option |  |  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value |  |  | Weighted Average Remaining Contractual Life |
Balance, June 30, 2023 |  |  |  | 1,541,500 |  |  | $ | 7.19 |  |  |  |  |  |  |  |  |
Granted |  |  |  | 1,625,000 |  |  |  | 2.99 |  |  |  |  |  |  |  |  |
Exercised |  |  |  | (7,800 | ) |  |  | 3.95 |  |  |  |  |  |  |  |  |
Cancelled/expired |  |  |  | (663,200 | ) |  |  | 5.88 |  |  |  |  |  |  |  |  |
Balance, June 30, 2024 |  |  |  | 2,495,500 |  |  |  | 4.78 |  |  |  |  |  |  |  |  |
Granted |  |  |  | 945,000 |  |  |  | 1.41 |  |  |  |  |  |  |  |  |
Exercised |  |  |  | (512 | ) |  |  | 1.40 |  |  |  |  |  |  |  |  |
Cancelled/expired |  |  |  | (419,988 | ) |  |  | 9.44 |  |  |  |  |  |  |  |  |
Balance, June 30, 2025 |  |  |  | 3,020,000 |  |  | $ | 3.09 |  |  | $ | 866 |  |  |  | 3.5 years |
As of June 30, 2025, 99.8% of the outstanding Options were fully vested. The total intrinsic value of Options exercised during the year ended June 30, 2025 was nil, and as of June 30, 2025, there was $4 of unrecognized compensation costs related to unvested share-based compensation arrangements granted. The Company recognized share-based compensation expense of $789 and $2,779 for the years ended June 30, 2025 and 2024, respectively. The following table summarizes the weighted average information and assumptions used to determine Option costs:
Schedule of weighted average and assumptions used to option costs |  | For the year ended June 30, |
|  | 2025 |  |  | 2024 |
Fair value per option granted during the period |  | $ | 0.84 |  |  | $ | 1.71 |
Risk-free interest rate |  |  | 4.44 | % |  |  | 4.25 | %
Expected dividend yield |  |  | 0 | % |  |  | 0 | %
Expected stock price volatility (historical basis) |  |  | 67.3 | % |  |  | 63.2 | %
Expected option life in years |  |  | 5.0 |  |  |  | 5.0 |
Prior to January 1, 2024, the Company concluded that under ASU 718, Compensation – Stock Compensation (Topic 718), Options previously issued on December 31, 2021, May 30, 2022, and March 27, 2023, which included a C$ strike price (the “CAD Options”) should remain equity-classified as management determined that the Options qualified for an exemption from liability classification as the CAD Options were denominated in a currency in which a substantial portion of the Company’s equity securities traded. Effective January 1, 2024, the Company determined that due to historically decreasing trading volume on the TSX, this exemption no longer applied and accordingly, these CAD Options were classified as a liability based on their fair values on that date. The Company recorded a mark-to-market gain of $147 in other operating expenses related to these CAD Option liabilities for the year ended June 30, 2024. The CAD Options expired at various dates during the year ended June 30, 2025, with no further gains or losses recorded in other operating expenses. On March 28, 2024, the Board approved a modification to Options previously issued on March 27, 2023, with dual strike prices of $6.95 and C$9.52, under which the option to exercise in C$ was removed. No other terms or conditions were amended by the Board. Based on this amendment, the Company re-classified these Options to equity on March 28, 2024, based on their fair value on that date.
| c) | Warrants
Warrant transactions are summarized as follows. Weighted average exercise prices related to Canadian dollar denominated Warrants were converted to U.S. dollars using end of period foreign currency exchange rates.
Schedule of Weighted average exercise prices |  | Warrants |  |  | Weighted Average Exercise Price |
Balance, June 30, 2023 |  |  | 18,816,304 |  |  | $ | 10.98 |
Granted |  |  | 1,593,817 |  |  |  | 3.33 |
Expired |  |  | (1,846,560 | ) |  |  | 8.67 |
Balance, June 30, 2024 |  |  | 18,563,561 |  |  |  | 10.53 |
Granted |  |  | 13,553,714 |  |  |  | 2.05 |
Exercised |  |  | (828,235 | ) |  |  | 1.78 |
Expired |  |  | (1,303,118 | ) |  |  | 7.72 |
Balance, June 30, 2025 |  |  | 29,985,922 |  |  | $ | 7.06 |
At June 30, 2025, the Company has outstanding exercisable Warrants, as follows:
Schedule of outstanding exercisable Warrants |  |  |  |  |  |
Number |  |  | Exercise Price |  |  | Expiry Date
| 250,000 |  |  | $ | 4.60 |  |  | September 1, 2025
| 413,432 |  |  |  | 3.54 |  |  | December 22, 2025
| 315,000 |  |  |  | 2.20 |  |  | June 24, 2026
| 1,117,090 |  |  |  | 1.75 |  |  | November 5, 2026
| 1,992,214 |  |  |  | 1.75 |  |  | November 13, 2026
| 615,385 |  |  |  | 3.25 |  |  | April 12, 2027
| 2,577,320 |  |  |  | 1.98 |  |  | August 2, 2027
| 15,666,626 | (1) |  |  | 11.50 |  |  | March 17, 2028
| 2,816,742 |  |  |  | 2.31 |  |  | September 17, 2028
| 1,288,660 |  |  |  | 2.05 |  |  | January 31, 2029
| 802,045 |  |  |  | 2.07 |  |  | November 5, 2029
| 1,067,946 |  |  |  | 2.07 |  |  | November 13, 2029
| 1,063,462 |  |  |  | 2.60 |  |  | No expiry
| 29,985,922 |  |  |  |  |  |  |
(1) | Includes 11,165,324 and 4,501,302 2023 Public Warrants and 2023 Private Warrants, respectively, as defined below. Each 2023 Public Warrant and 2023 Private Warrant is exercisable into 1.11829212 Common Shares.
In connection with the Closing, pursuant to the Business Combination Agreement, the Company assumed GXII’s obligations under the agreement (the “GXII Warrant Agreement”) governing the GXII share purchase Warrants (the “GXII Warrants”) and each GXII Warrant thereunder that was issued and outstanding immediately prior to the Closing Date was converted into one Warrant to purchase 1.11829212 Common Shares (the “NioCorp Assumed Warrants”) pursuant to the GXII Warrant Agreement, as amended by an Assignment, Assumption and Amendment Agreement, dated March 17, 2023, among the Company, GXII, Continental Stock Transfer & Trust Company, as the existing warrant agent, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A, together as the successor warrant agent (the “NioCorp Assumed Warrant Agreement”). In connection with the Closing, NioCorp issued (a) 9,999,959 public NioCorp Assumed Warrants (the “2023 Public Warrants”) in respect of the GXII Warrants that were publicly traded prior to the Closing and (b) 5,666,667 NioCorp Assumed Warrants (the “2023 Private Warrants”) to the Sponsor in respect of the GXII Warrants that it held prior to the Closing, which NioCorp Assumed Warrants were subsequently distributed by the Sponsor to its members in connection with the Closing. Each NioCorp Assumed Warrant entitles the holder to the right to purchase 1.11829212 Common Shares at an exercise price of $11.50 per 1.11829212 Common Shares (subject to adjustments for stock splits, stock dividends, reorganizations, recapitalizations and the like). No fractional shares will be issued upon exercise of any NioCorp Assumed Warrants, and fractional shares that would otherwise be due to the exercising holder will be rounded down to the nearest whole Common Share. In no event will the Company be required to net cash settle any NioCorp Assumed Warrant. 2023 Public Warrants The Company may elect to redeem the 2023 Public Warrants subject to certain conditions, in whole and not in part, at a price of $0.01 per 2023 Public Warrant if (i) 30 days’ prior written notice of redemption is provided to the holders, (ii) the last reported sale price of the Common Shares equals or exceeds approximately $16.10 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the Warrant holders and (iii) there is an effective registration statement covering the Common Shares issuable upon exercise of the 2023 Public Warrants, and a current prospectus relating thereto, available through the redemption date. Upon issuance of a redemption notice by the Company, the Warrant holders will have until the redemption date to exercise for cash, or, at the Company’s election, on a cashless basis. 2023 Private Warrants The 2023 Private Warrants: (i) will be exercisable either for cash or on a cashless basis at the holder’s option and (ii) will not be redeemable by the Company, in either case as long as the 2023 Private Warrants are held by the initial purchasers or their permitted transferees. Any 2023 Private Warrants that are held by someone other than the initial purchasers or their permitted transferees are treated as 2023 Public Warrants. The Company accounts for the 2023 Private Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the 2023 Private Warrants do not meet the criteria for equity treatment thereunder, the 2023 Private Warrants must be recorded as a liability. This liability is carried as a component of Warrant liabilities on the consolidated balance sheet and is subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to its current fair value, with the change in fair value recognized in the consolidated statement of operations and comprehensive loss. The Company will reassess the classification at each balance sheet date. As provided for in the NioCorp Assumed Warrant Agreement, through June 30, 2025, a total of 1,165,365 2023 Private Warrants were exchanged for 2023 Public Warrants. Upon exchange, the Company recorded an additional fair value expense of $26 and transferred the fair value of the exchanged 2023 Public Warrants from warrant liabilities to equity. The Company classifies the 2023 Private Warrants as Level 2 instruments under the fair value hierarchy and estimated the fair value using a Black Scholes model with the following assumptions:
Schedule of Company classifies the 2023 Private Warrants |  |  |  |  |  |  |  |
Key Valuation Input |  | June 30, 2025 |  |  | June 30, 2024 |
Stock price on valuation date |  | $ | 2.33 |  |  | $ | 1.73 |
Strike price |  | $ | 11.50 |  |  | $ | 11.50 |
Implied volatility of the 2023 Public Warrants |  |  | 90.0 | % |  |  | 69.0 | %
Risk free rate |  |  | 3.70 | % |  |  | 4.45 | %
Dividend yield |  |  | 0 | % |  |  | 0 | %
Expected Warrant life in years |  |  | 2.7 |  |  |  | 3.7 |
The change in the 2023 Private Warrants liability is presented below:
Schedule of change in the 2023 Private Warrants liability |  | Amount |
Valuation at June 30, 2023 |  | $ | 3,279 |
Change in valuation |  |  | (1,926 | )
Valuation at June 30, 2024 |  |  | 1,353 |
Exchange of 2023 Private Warrants for 2023 Public Warrants |  |  | (482 | )
Change in valuation |  |  | 1,661 |
Valuation at June 30, 2025 |  | $ | 2,532 |
Contingent Consent Warrants As consideration for entering into the previously publicly disclosed Waiver and Consent Agreement, dated September 25, 2022 (the “Lind Consent”), between the Company and Lind Global Asset Management III, LLC (“Lind III”), Lind III received, amongst other things, the right to receive additional Warrants (the “Contingent Consent Warrants”) if on September 17, 2024, the closing trading price of the Common Shares on the Toronto Stock Exchange or such other stock exchange on which such shares may then be listed, is less than C$10.00, subject to adjustments. The number of Contingent Consent Warrants to be issued, if any, is based on the Canadian dollar equivalent (based on the then current Canadian to U.S. dollar exchange rate as reported by Bloomberg, L.P.) of $5,000 divided by the five-day volume weighted average price of the Common Shares on the date of issuance. Further, the number of Contingent Consent Warrants issued would be proportionately adjusted based on the percentage of Warrants currently held by Lind III that are exercised, if any, prior to the issuance of any Contingent Consent Warrants. On September 17, 2024, the Company’s Common Share price was below the threshold price set forth in the Lind Consent, and accordingly, the Company issued 2,816,742 Contingent Consent Warrants to Lind III. Each Contingent Consent Warrant is exercisable for one Common Share at an exercise price of $2.308 and may be exercised at any time prior to their expiration on September 17, 2028. The number of Contingent Consent Warrants issued was based on $5,000 divided by the five-day volume weighted average price of the Common Shares on September 16, 2024. The Company valued the Contingent Consent Warrants at $2,262 based on a Black-Scholes valuation with the following inputs:
Schedule of Black-Scholes valuation |  |  |  |
Key Valuation Input |  | September 17, 2024 |
Closing Common Share price |  | $ | 1.74 |
Term (years) |  |  | 4.0 |
Historic equity volatility |  |  | 67.14 | %
Risk-free rate |  |  | 3.44 | %
The change in the fair value of the Contingent Consent Warrants liability is presented below:
Schedule of change in fair value of Warrants liability |  | Amount |
Valuation at June 30, 2024 |  | $ | 2,365 |
Fair value of Warrants issued |  |  | (2,262 | )
Gain on issuance of Warrants |  |  | (103 | )
Ending balance |  | $ | - |
The Company recognized a gain of $103 on the issuance of the Contingent Consent Warrants. This gain was recorded as a part of other gains in the condensed consolidated statements of operations and comprehensive loss.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration